1. Home
  2. RDI vs TPST Comparison

RDI vs TPST Comparison

Compare RDI & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

N/A

Current Price

$1.25

Market Cap

23.4M

ML Signal

N/A

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$0.98

Market Cap

26.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
TPST
Founded
1937
2011
Country
United States
United States
Employees
2005
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.4M
26.2M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
RDI
TPST
Price
$1.25
$0.98
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$11.00
AVG Volume (30 Days)
15.1K
82.8K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$295,000.00
Revenue This Year
$16.25
N/A
Revenue Next Year
$4.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.95
52 Week High
$1.65
$12.22

Technical Indicators

Market Signals
Indicator
RDI
TPST
Relative Strength Index (RSI) 46.94 23.64
Support Level $0.99 N/A
Resistance Level $1.26 $2.48
Average True Range (ATR) 0.06 0.08
MACD -0.01 0.00
Stochastic Oscillator 5.01 8.33

Price Performance

Historical Comparison
RDI
TPST

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: